These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases. Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782 [TBL] [Abstract][Full Text] [Related]
8. [Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation]. Liu QF; Fan ZP; Luo XD; Zhang Y; Sun J Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(44):3123-6. PubMed ID: 19159594 [TBL] [Abstract][Full Text] [Related]
9. Severe cold agglutinin disease caused by recurrent monomorphic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), clonally related to an EBV-negative plasmacytic hyperplasia in a pediatric multivisceral organ transplant recipient. Brunner B; Kropshofer G; Ellemunter H; Brunner A; Mueller T; Margreiter R; Tzankov A Pediatr Transplant; 2007 Aug; 11(5):547-51. PubMed ID: 17631026 [TBL] [Abstract][Full Text] [Related]
10. Can a microarray implicate human genes in post-transplant lymphoproliferative disorders? Davies M; Rowe D Pediatr Transplant; 2009 Dec; 13(8):944-7. PubMed ID: 20470354 [No Abstract] [Full Text] [Related]
11. Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications. Ong KW; Teo M; Lee V; Ong D; Lee A; Tan CS; Vathsala A; Toh HC Clin Cancer Res; 2009 Sep; 15(17):5350-8. PubMed ID: 19706821 [TBL] [Abstract][Full Text] [Related]
12. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. Rinaldi A; Kwee I; Poretti G; Mensah A; Pruneri G; Capello D; Rossi D; Zucca E; Ponzoni M; Catapano C; Tibiletti MG; Paulli M; Gaidano G; Bertoni F Br J Haematol; 2006 Jul; 134(1):27-36. PubMed ID: 16803564 [TBL] [Abstract][Full Text] [Related]
17. Complete absence of KSHV/HHV-8 in posttransplant lymphoproliferative disorders: an immunohistochemical and molecular study of 52 cases. Chen W; Huang Q; Zuppan CW; Rowsell EH; Cao JD; Weiss LM; Wang J Am J Clin Pathol; 2009 May; 131(5):632-9. PubMed ID: 19369621 [TBL] [Abstract][Full Text] [Related]
18. Utility of head and neck biopsies in the evaluation of posttransplant lymphoproliferative disorder. Campisi P; Allen UD; Ngan BY; Hawkes M; Forte V Otolaryngol Head Neck Surg; 2007 Aug; 137(2):296-300. PubMed ID: 17666259 [TBL] [Abstract][Full Text] [Related]
19. Significance of Epstein-Barr virus (EBV) load and interleukin-10 in post-transplant lymphoproliferative disorders. Muti G; Mancini V; Ravelli E; Morra E Leuk Lymphoma; 2005 Oct; 46(10):1397-407. PubMed ID: 16194885 [TBL] [Abstract][Full Text] [Related]